# IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2020

- Company: [IGC Pharma, Inc.](/companies/igc.md) (CIK 1326205)
- Form: 10-Q
- Filed: 2020-11-20
- Accepted by EDGAR: Nov 20, 2020, 16:06 ET
- Period: 2020-09-30
- Accession: 0001185185-20-001659
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1326205/000118518520001659/indiaglob20200930_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1326205/000118518520001659/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-01 to 2020-09-30 | $125.0k | us-gaap:Revenues |
| Revenue | 6 months, 2020-04-01 to 2020-09-30 | $709.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-07-01 to 2020-09-30 | $99.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2020-04-01 to 2020-09-30 | $637.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2020-07-01 to 2020-09-30 | $26.0k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2020-04-01 to 2020-09-30 | $72.0k | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-07-01 to 2020-09-30 | $219.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2020-04-01 to 2020-09-30 | $441.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2020-07-01 to 2020-09-30 | $1.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2020-04-01 to 2020-09-30 | $3.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-07-01 to 2020-09-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2020-04-01 to 2020-09-30 | −$3.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-07-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2020-04-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | −$1.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2020-04-01 to 2020-09-30 | −$3.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-07-01 to 2020-09-30 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2020-04-01 to 2020-09-30 | −$0.09 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2020-04-01 to 2020-09-30 | −$6.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2020-04-01 to 2020-09-30 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-09-30 | $1.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-30 | $13.7m | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $26.3m | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-30 | $2.7m | us-gaap:Liabilities |
| Long-term debt | at 2020-09-30 | $384.0k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2020-09-30 | $196.0k | us-gaap:ShortTermBorrowings |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1326205/000118518520001659/indiaglob20200930_10q.htm

Filed Nov 20, 2020.
Source: SEC EDGAR, the filing index for accession 0001185185-20-001659. Last ingested by Listed: Nov 6, 2026, 16:27 ET. No prices; not investment advice.
